Status:
COMPLETED
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
Lead Sponsor:
Alnylam Pharmaceuticals
Conditions:
Familial Amyloidotic Cardiomyopathy (FAC)
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to characterize the frequency of TTR mutations in subjects suspected of having cardiac amyloidosis
Eligibility Criteria
Inclusion
- Males or females \>18 years old
- History of evidence suggestive of cardiac amyloidosis
- Subject is willing and able to comply with protocol required assessments and provide written informed consent
Exclusion
- Known diagnosis of primary (AL) amyloidosis
- Known diagnosis of hereditary cardiomyopathy or cardiomyopathy due to aortic stenosis
- Patient is currently pregnant
Key Trial Info
Start Date :
June 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
1010 Patients enrolled
Trial Details
Trial ID
NCT02252653
Start Date
June 1 2014
End Date
March 1 2016
Last Update
July 20 2016
Active Locations (58)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Trial Site
Little Rock, Arkansas, United States
2
Clinical Trial Site
Bakersfield, California, United States
3
Clinical Trial Site
La Mesa, California, United States
4
Clinical Trial Site
Los Angeles, California, United States, 90073